ep ahead forecast revenu bit ep guidanc increas
ep estim consensu
guidanc busi ep growth increas cer prior
cer fx estim vs previous last publish estim
sale forecast product ahead
estim includ dupix aubagio travel vaccin lantu plavix allegra
cerdelga praluent combin estim product
forecast includ meningitis/pneumonia vaccin adult booster vaccin
toujeo lemtrada lovenox ambien cr combin
gpm estim
estim sg forecast
oper incom estim net incom attribut
non-control interest estim share profit
associ estim net financi expens
estim tax rate line share count also
dupix /eu approv adult/adolesc uncontrol asthma pdufa
phase data nasal polyp initi ph eosinophil esophag copd
praluent approv label includ odyssey cv data cemiplimab
 approv cutan squamou cell carcinoma pdufa isatuximab ph
data icaria file r/r mm initi ph mm sct elig patient
lemtrada initi ph ppm kevzara initi ph pmr gca rsv mab ph ii data
agonist ph ii data obes venglustat initi ph ii/iii
adpkd efpeglenatid initi two ph add-on cablivi caplacizumab eu
approv atpp fitusiran initi two ph studi hemophilia
initi ph ii copd ad eu gener busi divestitur ye
pleas see page report import disclosur
earn visibl remain limit diabet pressur new competit
way pipelin progress continu sanofi might stronger compani
praluent ip litig overhang sanofi product diversif emerg
market exposur improv consum presenc distinguish point dont
dupix approv adolescent/
praluent approv cv outcom
data label
cemiplimab /eu approv
lantu eros greater expect
sanofi sa formerli sanofi-aventi global diversifi health care compani base
franc compani focus field health care five growth platform diabet
solut human vaccin innov drug consum health care emerg market
compani portfolio prescript drug vaccin gener consum health
cowen compani
chg net sale sale profit expens oper profit/loss incom attribut non-control incom expens expens tax associ tax tax net incom per share share outstand estim cowen
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl lantu rare
diseas portfolio success pipelin product success deal patent
litig patent expir pressur biosimilar risk
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock sanofi adr secur
cowen compani act financi advisor acquisit busi sanfoi announc juli
author report own conting valu right sanofi adr
author report member author household long posit equiti secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc juli et dissemin juli et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
